458 related articles for article (PubMed ID: 12814972)
1. In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5.
Patki KC; Von Moltke LL; Greenblatt DJ
Drug Metab Dispos; 2003 Jul; 31(7):938-44. PubMed ID: 12814972
[TBL] [Abstract][Full Text] [Related]
2. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.
Williams JA; Ring BJ; Cantrell VE; Jones DR; Eckstein J; Ruterbories K; Hamman MA; Hall SD; Wrighton SA
Drug Metab Dispos; 2002 Aug; 30(8):883-91. PubMed ID: 12124305
[TBL] [Abstract][Full Text] [Related]
3. Ethanol inhibits in-vitro metabolism of nifedipine, triazolam and testosterone in human liver microsomes.
Patki KC; Greenblatt DJ; von Moltke LL
J Pharm Pharmacol; 2004 Aug; 56(8):963-6. PubMed ID: 15285839
[TBL] [Abstract][Full Text] [Related]
4. Effect of CYP3A5 expression on the inhibition of CYP3A-catalyzed drug metabolism: impact on modeling CYP3A-mediated drug-drug interactions.
Shirasaka Y; Chang SY; Grubb MF; Peng CC; Thummel KE; Isoherranen N; Rodrigues AD
Drug Metab Dispos; 2013 Aug; 41(8):1566-74. PubMed ID: 23723360
[TBL] [Abstract][Full Text] [Related]
5. Characterization of CYP3A isozymes involved in the metabolism of domperidone: role of cytochrome b5 and inhibition by ketoconazole.
Michaud V; Simard C; Turgeon J
Drug Metab Lett; 2010 Apr; 4(2):95-103. PubMed ID: 21281268
[TBL] [Abstract][Full Text] [Related]
6. Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms.
Perloff MD; von Moltke LL; Court MH; Kotegawa T; Shader RI; Greenblatt DJ
J Pharmacol Exp Ther; 2000 Feb; 292(2):618-28. PubMed ID: 10640299
[TBL] [Abstract][Full Text] [Related]
7. Allosteric activation of midazolam CYP3A5 hydroxylase activity by icotinib - Enhancement by ketoconazole.
Zhuang X; Zhang T; Yue S; Wang J; Luo H; Zhang Y; Li Z; Che J; Yang H; Li H; Zhu M; Lu C
Biochem Pharmacol; 2016 Dec; 121():67-77. PubMed ID: 27666601
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of cytochrome P450-3A inhibition by ketoconazole.
Greenblatt DJ; Zhao Y; Venkatakrishnan K; Duan SX; Harmatz JS; Parent SJ; Court MH; von Moltke LL
J Pharm Pharmacol; 2011 Feb; 63(2):214-21. PubMed ID: 21235585
[TBL] [Abstract][Full Text] [Related]
9. Drug interaction of efavirenz and midazolam: efavirenz activates the CYP3A-mediated midazolam 1'-hydroxylation in vitro.
Keubler A; Weiss J; Haefeli WE; Mikus G; Burhenne J
Drug Metab Dispos; 2012 Jun; 40(6):1178-82. PubMed ID: 22415932
[TBL] [Abstract][Full Text] [Related]
10. Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent.
Wang RW; Newton DJ; Liu N; Atkins WM; Lu AY
Drug Metab Dispos; 2000 Mar; 28(3):360-6. PubMed ID: 10681383
[TBL] [Abstract][Full Text] [Related]
11. Delineation of the interactions between the chemotherapeutic agent eribulin mesylate (E7389) and human CYP3A4.
Zhang ZY; King BM; Pelletier RD; Wong YN
Cancer Chemother Pharmacol; 2008 Sep; 62(4):707-16. PubMed ID: 18431572
[TBL] [Abstract][Full Text] [Related]
12. Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by alpha-naphthoflavone, terfenadine and testosterone.
Mäenpää J; Hall SD; Ring BJ; Strom SC; Wrighton SA
Pharmacogenetics; 1998 Apr; 8(2):137-55. PubMed ID: 10022752
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression.
Gibbs MA; Thummel KE; Shen DD; Kunze KL
Drug Metab Dispos; 1999 Feb; 27(2):180-7. PubMed ID: 9929500
[TBL] [Abstract][Full Text] [Related]
14. Covalent alteration of the CYP3A4 active site: evidence for multiple substrate binding domains.
Schrag ML; Wienkers LC
Arch Biochem Biophys; 2001 Jul; 391(1):49-55. PubMed ID: 11414684
[TBL] [Abstract][Full Text] [Related]
15. CYP3A5 Contributes significantly to CYP3A-mediated drug oxidations in liver microsomes from Japanese subjects.
Yamaori S; Yamazaki H; Iwano S; Kiyotani K; Matsumura K; Honda G; Nakagawa K; Ishizaki T; Kamataki T
Drug Metab Pharmacokinet; 2004 Apr; 19(2):120-9. PubMed ID: 15499178
[TBL] [Abstract][Full Text] [Related]
16. Evidence of significant contribution from CYP3A5 to hepatic drug metabolism.
Huang W; Lin YS; McConn DJ; Calamia JC; Totah RA; Isoherranen N; Glodowski M; Thummel KE
Drug Metab Dispos; 2004 Dec; 32(12):1434-45. PubMed ID: 15383492
[TBL] [Abstract][Full Text] [Related]
17. Unchanged cytochrome P450 3A (CYP3A) expression and metabolism of midazolam, triazolam, and dexamethasone in mdr(-/-) mouse liver microsomes.
Perloff MD; von Moltke LL; Cotreau MM; Greenblatt DJ
Biochem Pharmacol; 1999 Jun; 57(11):1227-32. PubMed ID: 10230766
[TBL] [Abstract][Full Text] [Related]
18. Defective activity of recombinant cytochromes P450 3A4.2 and 3A4.16 in oxidation of midazolam, nifedipine, and testosterone.
Miyazaki M; Nakamura K; Fujita Y; Guengerich FP; Horiuchi R; Yamamoto K
Drug Metab Dispos; 2008 Nov; 36(11):2287-91. PubMed ID: 18669585
[TBL] [Abstract][Full Text] [Related]
19. Inhibition and stimulation of intestinal and hepatic CYP3A activity: studies in humanized CYP3A4 transgenic mice using triazolam.
van Waterschoot RA; Rooswinkel RW; Sparidans RW; van Herwaarden AE; Beijnen JH; Schinkel AH
Drug Metab Dispos; 2009 Dec; 37(12):2305-13. PubMed ID: 19752211
[TBL] [Abstract][Full Text] [Related]
20. Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna-expressed human cytochrome P450.
Ghosal A; Satoh H; Thomas PE; Bush E; Moore D
Drug Metab Dispos; 1996 Sep; 24(9):940-7. PubMed ID: 8886602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
